Re-treatment with gefitinib in advanced lung adenocarcinoma
patients: a retrospective analysis
Takashi Kasai 1 , Hiroshi Soda 2 ,
Hiroshi Takatani 3 , Minoru Fukuda 4 ,
Reiji Nakano 3 ,
Akitoshi Kinoshita 3 , Masaaki Fukuda 3 ,
Seiji Nagashima 3 , Yoichi Nakamura 2 ,
Yoshifumi Soejima 3 ,
Mikio Oka 4 , Shigeru Kohno 2
1 Isahaya
General
Hospital, Nagasaki, Japan
2 Nagasaki
University
School of
Medicine
3 Nagasaki Thoracic
Oncology Group
4 Kawasaki
Medical
School
Background: Gefitinib is a selective EGFR tyrosine kinase
inhibitor, and has the anti-tumor activity for lung cancer. Recently, there are a few reports
about the efficacy of re-treatment with gefitinib in lung cancer patients. Methods: We retrospectively analyzed
patients with advanced lung adenocarcinoma, who received re- treatment with gefitinib in NTOG hospitals.
We informed patients about predictive effects and adverse events of this re-treatment. Results: A total of
eight patients with stage IV disease were analyzed. The patients characteristics were as follows; median age
(range) = 63 (49-80), male/female = 2/6, PS0/1/2/3/4 = 0/4/1/2/1, smoker/non-smoker = 2/6. First line gefitinib
treatment showed the effectiveness in seven and no response in another one. The reasons of discontinue of
first line gefitinib therapy were liver dysfunction in two and tumor progression in another six. Re-treatment with
gefitinib showed the efficacy in six and disease progression in two. In six responders by re-treatment, five
patients had tumor progression after the first line therapy. These five patients were male/female = 1/4,
smoker/non-smoker = 1/4. Mild tumor reduction and improve of symptom were achieved in three and decrease
of CEA levels in two of these five patients. Conclusions: Re- treatment with gefitinib may have the
efficacy to selected patients with gefitinib resistant lung adenocarcinoma
重
新使用iressa治疗晚期肺腺癌患者的回顾分析:
Takashi Kasai 1 , Hiroshi Soda 2 ,
Hiroshi Takatani 3 , Minoru Fukuda 4 ,
Reiji Nakano 3 ,
Akitoshi Kinoshita 3 , Masaaki Fukuda 3 ,
Seiji Nagashima 3 , Yoichi Nakamura 2 ,
Yoshifumi Soejima 3 ,
Mikio Oka 4 , Shigeru Kohno 2
1谏早总医院, 长崎, 日本
2日本长崎大学医学院,长崎胸部肿瘤组
4长崎医学院
背景
iressa是一种选择性EGFR酪氨酸激酶抑制剂,并具有抗肿瘤活性,为肺癌. 最近,有一些报道了重
新使用iressa治疗肺癌患者疗效.
方法:
回顾分析,12例中晚期肺腺癌,他们接到重
新使用iressa的治疗,在NTOG
医院. 我们告诉病人重
新使用iressa的预测疗效和不良后果. 结果:
一共有八个第四期患者进行了分析. 病人的特点如下; 年龄中位数(范围) = 63 ( 1949年至1980年) ,男/女= 2 / 6 , PS 0/1/2/3/4 = 0/4/1/2/1 , 抽烟/不抽烟= 2 / 6 . 第一线治疗显示七患者有效果, ,在另一患者没有反应.
停止一线治疗原因,两人肝功能不正常,另外6人癌进展. 重新使用IRESSA在六个病人显示效果,另外两人癌进展. 在六个有反应的病人中, 其中5例是第一线治疗肿瘤有效后又进展的. 这5例中,男/女= 1 / 4 ,抽烟/不抽烟= 1 / 4, 5人中,三个取得了
轻度肿瘤减小和改善症状,
两艘CEA水平下降。
结论
对选定的对IRESSA抗药的肺腺癌患者,重
新使用Gefitinib可以有 |